Goodwin Life Sciences partner Wendy Pan will be moderating the "Globalization Through Cross-Border Partnerships" fireside chat at the 2022 Sino-American Pharmaceutical Professionals Association (SAPA) Healthcare Investment Forum.
The fireside chat will focus on how China biopharmas seeking to develop therapies for U.S. approval must adapt to new FDA demands for multi-regional clinical trials. Chinese players increasingly will need partners for clinical development in the West. How will this new driver of U.S.-China collaborations affect partnering strategy and how can both sides build value?
Wenseng “Wendy” Pan, J.D. & Ph.D.Partner